類肉瘤病：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 預計到 2035 年，法國類肉瘤病市場將從約 2,200 萬美元成長到 5,500 萬美元，這表明市場將大幅擴張。
• 以下因素正在推動市場成長：
• 在慢性疾病的治療中，免疫抑制療法和生物製藥的使用日益增加。
• 診斷方法的改進和多器官疾病長期監測的進步
• 市場規模的擴大是由治療週期延長和疑難雜症先進療法的日益普及所推動的。
• 未來的成長取決於標靶免疫調節療法的發展以及慢性進行性類肉瘤病管理策略的改進。

類肉瘤病概述

類肉瘤病是一種多器官肉芽腫性疾病，其病因尚未完全明確。在具有遺傳易感性的個體中，由於先天性和適應性免疫反應對未知抗原觸發因素的失調，導致受累器官中出現由活化巨噬細胞、上皮樣細胞和CD4+ T淋巴細胞組成的非乾酪性肉芽腫病理性積聚。超過90%的病例病變位於肺部和胸內淋巴結，常涉及皮膚、眼、肝、脾、心臟和神經系統。患者的臨床表現多種多樣，從偶然發現的無症狀病例到急性、通常可自發性緩解的洛夫格倫症候群（Lofgren's syndrome），後者以雙側肺門淋巴結腫大、結節性紅斑和關節炎為特徵。患者也可能伴隨慢性呼吸困難、乾咳、疲倦和器官特異性觀察。診斷需綜合考慮臨床、觀察和組織病理學觀察。乳房攝影篩檢應觀察雙側肺門淋巴結腫大，血清血管緊張素轉化酶（ACE）和可溶性白細胞介素-2受體（sIL-2R）水平升高可作為輔助診斷生物標記進行確認，切片檢查應明確是否存在非乾酪性肉芽腫，並應排除感染疾病和惡性腫瘤等類似疾病。對於有症狀或病情進展的病例，糖皮質激素仍是治療的基礎；而對於慢性疾病，胺基甲基葉酸和Azathioprine則可作為糖皮質激素替代療法。對於難治性病例，抗TNF生物製藥，包括羥氯喹和Infliximab，可能有效。由於存在危及生命的併發症風險，類肉瘤病和類肉瘤病需要特別密切的後續觀察。預後因病例而異。雖然許多病例可自發性緩解，但慢性進行性疾病需要長期的多學科後續觀察和以患者為中心的輔助治療。

主要亮點

• 在法國，預計到 2025 年，類肉瘤病病患者人數將約為 22,210 人，到 2035 年將增加至近 23,815 人，反映出該疾病負擔的逐漸增加。
• 肺類肉瘤病仍然是主要的臨床表現，佔確診病例的大多數。
• 慢性進行性疾病和肺外病變仍是導致長期發生率的重要因素。
• 皮質類固醇仍然是標準治療方法，但由於類固醇的長期毒性，減少類固醇使用的免疫抑制療法的使用正在增加。
• 人們對標靶生物製藥療法的興趣日益濃厚，這為難治性和重症類肉瘤病病患者提供了更多治療選擇。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Sarcoidosis Market Outlook

Thelansis's "Global Sarcoidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sarcoidosis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Sarcoidosis Overview

Sarcoidosis is a multisystem granulomatous disorder of incompletely understood aetiology, characterised by the pathological accumulation of non-caseating granulomas - composed of activated macrophages, epithelioid cells, and CD4+ T-lymphocytes - in affected organs, driven by dysregulated innate and adaptive immune responses to unidentified antigenic triggers in genetically susceptible individuals. The lungs and intrathoracic lymph nodes are involved in over 90% of cases, with frequent additional involvement of skin, eyes, liver, spleen, heart, and nervous system. Patients present heterogeneously - ranging from asymptomatic incidental discovery to Lofgren syndrome, an acute, typically self-limiting presentation of bilateral hilar lymphadenopathy, erythema nodosum, and arthritis - alongside chronic dyspnoea, dry cough, fatigue, and organ-specific manifestations. Diagnosis integrates clinical, radiological, and histopathological findings; chest imaging demonstrating bilateral hilar lymphadenopathy, elevated serum ACE and sIL-2R as supportive biomarkers, and biopsy confirming non-caseating granulomas while excluding infectious and malignant mimics. Corticosteroids remain the therapeutic cornerstone for symptomatic or progressive disease, with methotrexate and azathioprine as steroid-sparing agents for chronic disease. Refractory cases may benefit from hydroxychloroquine or anti-TNF biologics including infliximab. Cardiac and neurosarcoidosis demand particularly vigilant monitoring given life-threatening complication risk. Prognosis varies considerably; spontaneous remission occurs in many, while chronic progressive disease necessitates long-term multidisciplinary surveillance and patient-centred supportive management.

Key Highlights

• In France, sarcoidosis prevalence cases are projected to increase from approximately 22,210 in 2025 to nearly 23,815 by 2035, reflecting a gradual increase in disease burden.
• Pulmonary sarcoidosis remains the predominant clinical presentation, accounting for the majority of diagnosed cases.
• Chronic progressive disease and extrapulmonary involvement continue to contribute significantly to long-term morbidity.
• Corticosteroids remain the standard of care; however, long-term steroid toxicity drives increasing use of steroid-sparing immunosuppressive therapies.
• Growing interest in targeted biologic therapies is expanding treatment options for refractory and severe sarcoidosis cases.

Market Overview

• The France sarcoidosis market is projected to grow from approximately $22 MN to $55 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing use of immunosuppressive and biologic therapies in chronic disease management
• Improved diagnosis and long-term monitoring of multisystem disease involvement
• Market value growth is driven by prolonged treatment duration and increasing adoption of advanced therapies in refractory disease.
• Future growth will depend on development of targeted immunomodulatory therapies and improved management strategies for chronic progressive sarcoidosis.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)